• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Indonesia·Healthcare·BMHS.JK
Share

PT Bundamedik Tbk Stocks

IDR 184Last Updated 09.11.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

IDR 98.08M

IDR 184
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Weak growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Beyond its direct medical services, the company diversified into the distribution of pharmaceuticals and medical equipment, alongside interests in the hotel industry, medical tourism, and management consulting. Established in 1973, PT Bundamedik Tbk is headquartered in Jakarta Pusat, Indonesia, and operates as a subsidiary of PT Bunda Investama Indonesia.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair value on EV/

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of BMHS.JK is 220 and suggests 19.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.11.2026 05:26

Nebius's Nvidia-backed competitor may postpone its IPO — The Telegraph

11.11.2026 02:45

CoreWeave exceeded Wall Street's expectations. Will this ease concerns about neo-clouds?

11.11.2026 02:17

Stocks fell, and bonds experienced one of their biggest sell-offs: the market is waiting for the Fed to act

11.11.2026 01:51

Money managers seek shelter from AI risks in emerging markets. What are they buying?

11.11.2026 00:09

Boeing books most October aircraft orders in almost three decades

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026